Abnova Introduce CytoQuest™ CR, a Non-Invasive Circulating Cell Isolation and Retrieval System
Neihu, Taiwan (January 6, 2014)
Abnova Corporation announced today the introduction of CytoQuest™ CR system developed by Abnova team at Neihu and Dr. Hsian-Rong team at UCLA California NanoSystem Institute. CytoQuest™ CR is a non-invasive, circulating cell isolation and retrieval system for circulating tumor cells (CTCs), circulating stem cells (CSCs), and circulating fetal cells (CFCs). The interrogation of circulating cells and access to their intact DNA and protein repertoire represent the next generation “real-time” analysis which not only complements but also fills the unmet need of traditional tissue and serum based tests. The new system will be one of the key drivers for Abnova’s product and service revenue generation in translational and clinical research markets in 2014.
By combining multi-disciplinary expertise in monoclonal antibody engineering and FISH probe manufacturing with fluidics, nano-substrate, polymer chemistry, and thermal control technologies, Abnova has integrated a robust CytoQuest™ CR system and bioreagent platform under ISO13485 standardization for, non-invasive isolation and retrieval of CTCs for new drug
development, prediction and monitoring of disease progress and treatment response, and CFCs for prenatal diagnosis. According to Transparency Market Research, the circulating tumor cell market is expected to reach $7.9 billion in 2018. The size of the prenatal testing industry will grow to $1.6 billion by 2017 according to Frost & Sullivan.
As an adjunctive strategy for future revenue growth , Abnova intends to develop the CytoQuest™ CR system into a full-fledged in vitro diagnostic (IVD) platform in 2014 by satisfying FDA guidelines for system engineering and integration. This also pave the way for application-driven (instrument plus bioreagent) clinical trial and FDA submission in 2015.
----------------------------------------------------------------------------------------------------------------------------------------------------------------
About Abnova
Abnova has established a comprehensive portfolio of fully integrated solutions and services to address the needs of the clinical research and in vitro diagnostic industry. Abnova’s ISO13485 and GMP certified facility, and medical service laboratory provide its customers access to rabbit monoclonal antibody, ELISA kit, FISH probe, and circulating cell isolation and retrieval system.
|
